The drug works by opening specific potassium channels in the brain, calming overactive neurons. Interestingly, it doesn’t need dose adjustments or titration; a big plus for patients already taking multiple epilepsy meds. In trials, it cut seizure frequency by over 50% in many patients; far better than placebo. This could be a game-changer, especially since the last drug in this class was pulled off the market in 2017. The company is now waiting for FDA review, with potential approval expected next year. If greenlit, azetukalner might offer new hope for millions living with uncontrolled seizures; without the side effects that took its predecessor off shelves.